For instance, in rodent models of metabolic-associated fatty liver disease (MAFLD) and obesity-related insulin resistance, PFD administration improved insulin sensitivity, reduced hepatic steatosis, and attenuated pro-inflammatory signaling pathways [35, 36]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.